伊顿制药

最新新闻

• 公司公告
  4: Eton Pharmaceutical | 4: Statement of changes in beneficial ownership of securities-10% Owner Opaleye Management Inc.
  SEC · 2026/7/8
• 评级变动
  CCORF Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Maintains Target Price $60
  \u5e02\u573a\u8d44\u8baf · 2026/7/30
• 公司公告
  4/A: Eton Pharmaceutical | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-10% Owner Opaleye Management Inc.
  SEC · 2026/7/18
• H.C. Wainwright Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Maintains Target Price $70
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  B. Riley Adjusts Price Target on Eton Pharmaceuticals to $70 From $40, Maintains Buy Rating
  MT Newswires · 2026/8/14
• Eton Pharmaceutical(ETON.US) Officer Sells US$6.09 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/8/21
• 评级变动
  H.C. Wainwright Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Raises Target Price to $65
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• 评级变动
  Craig-Hallum Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Announces Target Price $62
  \u5e02\u573a\u8d44\u8baf · 2026/7/28
• Eton Pharmaceuticals (ETON) Gets a Buy From H.C. Wainwright
  TipRanks · 2026/10/1
• 评级变动
  H.C. Wainwright Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Raises Target Price to $70
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  Craig-Hallum Maintains Eton Pharmaceutical(ETON.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/5/22
• 公司公告
  Eton Pharmaceutical | 4: Statement of changes in beneficial ownership of securities-Officer Gruber James R.
  SEC · 2026/1/15
• 评级变动
  B. Riley Securities Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/6/27
• 评级变动
  Craig-Hallum Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Maintains Target Price $62
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• Upgrade: Analysts Just Made A Notable Increase To Their Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Forecasts
  Simply Wall St · 2026/8/19
• 评级变动
  CCORF Initiates Eton Pharmaceutical(ETON.US) With Buy Rating, Announces Target Price $60
  \u5e02\u573a\u8d44\u8baf · 2026/7/17
• Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO (Miltefosine) Capsules
  GlobeNewswire · 2026/9/28
• 公司公告
  3: Eton Pharmaceutical | 3: Initial statement of beneficial ownership of securities- Matthews Judith M.
  SEC · 2026/6/2
• 评级变动
  Craig-Hallum Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Raises Target Price to $76
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 公司公告
  4: Eton Pharmaceutical | 4: Statement of changes in beneficial ownership of securities-10% Owner Opaleye Management Inc.
  SEC · 2026/7/17

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。